ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.

Features

Auto Apply Resume Optimizer Cover Letter Optimizer Interview Prep

Company

Social Media

Need Help?

team@applyblast.com

VP Clinical Development and Global Program Lead (GPL) for Lung Cancer at Erasca - ApplyBlast

VP Clinical Development and Global Program Lead (GPL) for Lung Cancer

Erasca

2 months ago

San Diego, California, United States

Onsite

Full Time

Executive

0 applicants

View Job Listing

Apply to 100+ jobs

About this role

The Vice President of Clinical Development and Global Program Lead will provide medical leadership and oversight for Erasca's lung cancer development program, shaping strategy, protocol design, and regulatory filings while serving as a hands‑on drug developer and clinical lead on studies. Reporting to the Chief Medical Officer, the role collaborates across the portfolio to drive data‑driven decision making and advance the company's mission to erase cancer.

Responsibilities

Provide medical direction and strategy for lung cancer program
Lead clinical development subteam and oversee study integrity
Drive regulatory filings and health authority interactions

Skills

Qualifications

MDOncology Board CertificationFellowship training in Oncology

About Erasca

erasca.com

Headquarters

San Diego, California, United States

Company Size

51-200 employees

Founded

2018

View Profile

Erasca is a clinical-stage precision oncology company on a mission “to erase cancer,” focused on therapies that shut down the RAS/MAPK signaling cascade — one of the most commonly mutated cancer pathways. Its pipeline comprises targeted programs that attack the RAS/MAPK pathway at multiple nodes, with the goal of addressing cancers driven by these mutations (a pathway that affects roughly 5.5 million people worldwide each year). By developing precision small molecules and combination strategies, Erasca aims to deliver transformative treatments that improve outcomes across a broad range of devastating cancers.